Company news

Veracyte, Inc. news in 2025

Veracyte, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 28, 2025

Veracyte to Participate in Upcoming Investor Conferences

November 5, 2025

Veracyte Announces Third Quarter 2025 Financial Results

November 3, 2025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

November 2, 2025

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

October 14, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

September 27, 2025

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

September 23, 2025

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

September 8, 2025

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 28, 2025

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

August 26, 2025

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

August 25, 2025

Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care

August 7, 2025

Veracyte Announces Second Quarter 2025 Financial Results

August 6, 2025

Veracyte Set to Join S&P SmallCap 600

July 24, 2025

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

July 16, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

July 7, 2025

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 27, 2025

Veracyte Announces First Quarter 2025 Financial Results

May 6, 2025

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

April 24, 2025

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

April 21, 2025

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

April 20, 2025

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

April 15, 2025

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

March 24, 2025

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

March 18, 2025

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

February 23, 2025

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

February 13, 2025

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

February 10, 2025

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

February 4, 2025

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

February 3, 2025

Calls in 2025

Decks in 2025